‘Cutting Edge Science for Parkinson’s Clinicians’ is open to health professionals involved in the management and treatment of Parkinson’s disease (final year registrars and above).

Meeting 2019

The 2nd Annual Scientific Meeting designed to advance scientific insights for PD specialists took place on 25 & 26 June 2019 in Birmingham.

Now in its second year the meeting was a sell-out again and expectations were high. Chaired by Dr Peter Fletcher (Gloucestershire Hospitals NHS Foundation Trust), the meeting was designed to cater to the diverse needs and interests of its varied audience of neurologists, care of the elderly physicians, psychiatrists and Parkinson’s nurses.

This year, the meeting’s theme was to ‘Question everything’, to review what we already know, and to think about how clinical observations and cross-team collaborations can drive us forward.

This meeting was designed and delivered by the Parkinson’s Academy and sponsored by Bial Pharma. The sponsor has had no input into the educational content or organisation of this meeting.

Programme 2019

What is the relationship between ageing, frailty and Parkinson’s disease?

Prof Richard Walker, Geriatrician, University of Newcastle

“Increasing age is the main non-modifiable risk for Parkinson’s. It is also the main risk factor for frailty” said Professor Richard Walker (University of Newcastle) as he started his presentation. There is no universally agreed definition of frailty, yet we all can recognise a frail patient when we meet […]

Continue Reading »


How do dementia, psychosis and Parkinson’s disease overlap with each other?

Prof Iracema Leroi, Associate Professor in geriatric psychiatry, Trinity College, Dublin

“Parkinson’s is now recognized as a multifaceted disorder, with considerable non-motor symptoms characterizing the disease course” opened Professor Iracema Leroi (Trinity College, Dublin). Neuropsychiatric symptoms in PD include dementia, psychosis, depression, anxiety, […]

Continue Reading »


What have we learnt from the GDNF study?

Dr Alan Whone, Neurologist, University of Bristol

Dr Alan Whone opened his presentation of the pioneering GDNF study by answering the question posed – “We have learned a lot!”. Although the study did not meet its primary endpoint, many interesting findings can be realised in the data, and it would be wrong to view this study as a failure. […]

Continue Reading »


Opicapone: The promise of the theory

Dr Camille Carroll, Associate Professor and Honorary Consultant Neurologist, University of Plymouth

Parkinson’s disease clinicians are increasingly looking towards personalised medicine, where an understanding of phenotypic subtypes guides treatment decisions, but how to reconcile this move with the introduction of new drugs such as opicapone […]

Continue Reading »


Prodromal PD – Fact or fiction?

Dr Alastair Noyce, Neurologist, Queen Mary University of London

“While the diagnosis of Parkinson’s disease (PD) remains focused on motor symptoms, the underlying pathological process clearly starts many years before these overt signs” began Dr Alastair Noyce (Queen Mary University London). In this ‘prediagnostic’ phase, a diverse […]

Continue Reading »


How can we target the disease mechanisms in Parkinson’s disease?

Dr Simon Stott, Deputy Director of Research & Development, The Cure Parkinson’s Trust

“There is currently a great deal of research being conducted on Parkinson’s disease. The Cure Parkinson’s Trust is involved in 17 trials and patients are desperate for information” stated Dr Simon Stott of The Cure Parkinson’s Trust. PD is a multifactorial disease, where both […]

Continue Reading »


Non-pharmacological therapies: An evidence free zone?

Prof Bas Bloem, Medical Director, Parkinson Center Nijmegen (ParC)

Current medical management is only partially effective in controlling the symptoms and signs of Parkinson’s disease (PD). Medication mainly targets impairments related to dopaminergic lesions and is, therefore, not effective for symptoms that are largely related to non-dopaminergic lesions, such as impaired balance or […]

Continue Reading »


Double Dutch – Case presentation by Prof Bas Bloem

Prof Bas Bloem, Medical Director, Parkinson Center Nijmegen (ParC)

Using a series of cases, Professor Bastiaan Bloem (Director, Parkinson Center, Nijmegen, The Netherlands) underscored the importance of clinical observation in his daily practice. The first case was of a professional violinist whose tremor resulted in him retiring from his passion. Professor Bloem explained that this […]

Continue Reading »


Has Parkinson’s treatment really changed?

Drs Andrea Lindahl, Lara Teare & Lucy Strens, Consultant Neurologists, and Hannah Martin, Parkinson’s Disease Nurse Specialist, University Hospitals Coventry and Warwickshire NHS Trust

Taking a tongue in cheek approach to history, the Coventry & Warwickshire Parkinson’s Team (Hannah Martin, Lucy Strens, Lara Teare and Andrea Lindahl) took us on a whirlwind tour of Parkinson’s through the ages. Ancient texts found in China, India, Greece (and even the Bible) did not refer to the syndrome as Parkinson’s […]

Continue Reading »


Meeting 2018

The first Annual Scientific Meeting designed to advance scientific insights for PD specialists took place on 4 July 2018 in Birmingham.

This one-day meeting was chaired by Dr Peter Fletcher and attended by a diverse audience of neurologists, care of the elderly physicians, psychiatrists and Parkinson’s nurses. The meeting was a chance to review advances in the clinical understanding of Parkinson’s and discuss how to build on these insights in routine clinical practice.

This meeting was supported by Bial and delivered in association with the Parkinson’s Academy.

Programme 2018

Where are we with deep brain stimulation?
Dr Ben Wright, University Hospitals Birmingham NHS Foundation Trust

Is postural instability the clinical cornerstone of Parkinson’s diagnosis?
Dr Emily Henderson, University of Bristol and Royal United Hospitals Bath NHS Foundation Trust

Personalised medicine in Parkinson’s: From theory to reality
Prof K. Ray Chaudhuri, Kings College and Institute of Psychiatry

Where are we going with medications?
Dr Daniel van Wamelen, King’s College London

Do we need to rethink imaging?
Dr Donald Grosset, Queen Elizabeth University Hospital, Glasgow

Do we need to rethink genetic testing?
Prof Huw Morris, University College London